India Continuous Glucose Monitoring Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Application (Diabetic Patients, Critical Patients), And By End User Industry (Hospitals, Diagnostic Centers And Clinics, Home Care) - Forecasts From 2023 To 2028

  • Published : Apr 2023
  • Report Code : KSI061614939
  • Pages : 80

The India Continuous Glucose Monitoring Market is projected to grow at a CAGR of 16.55% during the forecast period to reach US$13.656 million by 2028, from US$4.674 million in 2021.

Continuous glucose monitoring or CGM is a wearable medical device that continuously tracks blood sugar levels for people with type 1 and type 2 diabetes. Tracking blood sugar levels is extremely essential for diabetic patients as they have to make sure when to take insulin and CGM devices help them in determining that. CGM is a widely used technology as it is advantageous for diabetics. Studies have shown that the use of CGM devices ensures a shorter duration of hypoglycemia or a lower level of glycated haemoglobin. In India, the continuous glucose monitoring market is segmented by application and end-user.

The growing prevalence of type 1 and type 2 diabetes, continuous product launches by key market players along with rising government initiatives and programmes to educate people about diabetic health & care are some of the key determinants which are positively impacting the demand for CGM devices in this country.

However, the high price of CGM devices and the lack of reimbursement policies by the national medical insurance provider in this country is obstructing the growth of the Indian market for continuous glucose monitoring devices during the analysis period.

During the anticipation period, the growing incidences of diabetes will support the growth of the Indian continuous glucose monitoring market during the projection period.

One of the primary factors driving the growth of continuous glucose monitoring devices in India is the high prevalence of type 1 and type 2 diabetes among the population. According to the statistics presented by the International Diabetes Federation, 8.3 per cent of Indian adults, or more than 74 million people, have diabetes in 2021. This number is expected to reach 124.8 million by 2045. Moreover, 40 million people have impaired glucose tolerance in this country, which puts them at a greater risk of becoming type 2 diabetes. This number is anticipated to reach 65.5 million by 2045. Those who have diabetes run the risk of significant and fatal consequences like heart attack, kidney failure, blindness, and lower limb amputation. This leads to a lower quality of life and higher medical expenditure. The prevalence of diabetes has alarmingly increased across India in recent years, reaching an all-time high mostly due to lifestyle changes. According to IDF data, India has the second highest number of people at risk of Type 2 diabetes with 40 million. Diabetes is also one of the leading causes of death in India. According to IDF data, nearly 647.8 thousand people died due to diabetes. Diabetic patients must make several adjustments throughout the day to keep their blood glucose levels within acceptable ranges. Therefore CGM devices are extremely crucial for them. The decreasing cost of CGM devices in the country is also propelling market demand.

Various policies, programs and services related to diabetes by the government to spur growth during the projection period.

To combat risk factors like obesity and other medical conditions, the Indian government has implemented several reforms over the years to improve the distribution of doctors, create new types of service organisations, introduce new financing models, and implement a variety of quality improvement initiatives and policy frameworks in the healthcare sector. This also emphasizes chances for sustaining and growing advancements in the provision of diabetes care and the application of diabetes technologies.

Initiatives implemented by the Indian government are anticipated to fuel the market's expansion. For instance, in December 2022, the Government of India provided free essential medicines like insulin and subsidies on diabetes-related medical devices to people suffering from Type 1 and Type 2 diabetes under the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke.

In order to assure cheap pricing for devices, the Indian Federal Government collaborated with a large number of private businesses to use their supply chain. With the introduction of new technologies, continuous glucose monitoring devices are becoming more affordable, which is projected to boost the segment's growth throughout the forecast period.

Market Key Developments

  • In November 2020, Abbott announced that its FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, is available for adults, children (over the age of four), and women who are living with diabetes in India. This gives them the option to check their blood glucose levels at any time and anywhere, ultimately improving glucose control. This device can also be used by women with gestational diabetes (diabetes during pregnancy).
  • In January 2022, a revolutionary Hyderabad-based Health-tech company  BlueSemi launched a completely non-invasive glucose monitor called EYVA. he non-invasive consumer health technology device is supported by a ground-breaking proprietary technology that makes use of sensor fusion, precise AI algorithms, and advanced IoT.
  • In March 2022, Medtronic debuted the MiniMed 780G system in India. The MiniMed 780G system is a cutting-edge closed-loop CGM insulin pump device for people with type 1 diabetes who are between the ages of 7 and 80.


  • By Application
    • Diabetes Patients
    • Critical Patients
  • By End User
    • Hospitals
    • Diagnostic Centers & Clinics
    • Home Care 


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Diabetes Patients

5.3. Critical Patients


6.1. Introduction

6.2. Hospitals

6.3. Diagnostic Centers & Clinics

6.4. Home Care


7.1. Major Players and Strategy Analysis

7.2. Emerging Players and Market Lucrativeness

7.3. Mergers, Acquisitions, Agreements, and Collaborations

7.4. Vendor Competitiveness Matrix


8.1. Abbott Laboratories

8.2. Dexcom, Inc.

8.3. Medtronic plc

8.4. Roche Diabetes Care, Inc.

8.5. Ypsomed AG

8.6. Senseonics Holdings, Inc.


8.7. ARKRAY Inc.

Abbott Laboratories

Dexcom, Inc.

Medtronic plc

Roche Diabetes Care, Inc.

Ypsomed AG

Senseonics Holdings, Inc.



Related Reports

Report Name Published Month Get Sample PDF